HWHG(SH:600079) Xin Lang Zheng Quan·2025-11-04 05:59Core Viewpoint - The stock price of Renfu Pharmaceutical has experienced a decline of 11.93% year-to-date, with a notable drop of 2.03% on November 4, 2023, indicating potential challenges in the company's market performance [1]. Financial Performance - For the period from January to September 2025, Renfu Pharmaceutical reported a revenue of 17.883 billion yuan, reflecting a year-on-year decrease of 6.58%. However, the net profit attributable to shareholders increased by 6.22% to 1.689 billion yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 3.113 billion yuan, with 1.779 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Renfu Pharmaceutical reached 69,400, an increase of 38.71% from the previous period. The average circulating shares per person decreased by 27.91% to 22,222 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 42.1832 million shares, a decrease of 1.3907 million shares from the previous period [3].